Professor Michel Coleman BA BM BCh MSc FFPH
- Michel Coleman's Contacts
- Cancer Research UK Cancer Survival Group
- Keppel Street
- WC1E 7HT
- T: +44 (0)20 7927 2551
- F: +44 (0)20 7436 4230
- Follow me
Since 1995, he has been Professor of Epidemiology and Vital Statistics at the London School of Hygiene & Tropical Medicine. He was Deputy Chief Medical Statistician at the Office for National Statistics from 1995 to 2004 and Head of the Cancer and Public Health Unit at the School from 1998 to 2003. He has previously worked for the World Health Organisation at the International Agency for Research on Cancer in Lyon (1987-1991), and was Medical Director of the Thames Cancer Registry in London (1991-1995). His main interests include trends in cancer incidence, mortality and survival, and the application of these tools to the public health control of cancer.
He teaches on the MSc Epidemiology and other Master's courses, and supervises research degree students. He co-directs the annual short course on cancer survival with Dr Bernard Rachet and Dr Claudia Allemani, and is often invited to teach in other countries.
We are funded by Cancer Research UK as the Cancer Survival Group to quantify, describe and explain patterns and trends in cancer survival by socio-economic group, geographic area and ethnicity, in collaboration with many research partners in the UK and around the world. We develop methodology and tools for survival analysis. We maintain a STATA program for relative survival analysis (strel2), freely available on the web; it has been downloaded by more than 400 partners world-wide. We produce cancer survival estimates at various geographic levels for the NHS, Government and NHS England for the NHS Outcomes Framework Indicators and the Public Health Framework Indicators.
In August 2008, we published the first world-wide comparison of cancer survival up to 1999 among 1.9 million patients diagnosed with cancer of the breast (F), colon, rectum or prostate in 31 countries on five continents (CONCORD study).
In March 2015, we initiated global surveillance of cancer survival, by analysing individual data for 25.7 million patients diagnosed during the 15 years 1995-2009 with one of 10 cancers, in collaboration with 279 cancer registries in 67 countries world-wide (CONCORD-2 study).
- Capacity strengthening
- Disease control
- Global Health
- Health care policy
- Health inequalities
- Health outcomes
- Health policy
- Health systems
- International comparisons
- Public health
- Statistical methods
Disease and Health Conditions
- Cervical cancer
- Non-communicable diseases
- Arab World
- Caribbean small states
- East Asia & Pacific (all income levels)
- East Asia & Pacific (developing only)
- Euro area
- Europe & Central Asia (all income levels)
- European Union
- Antigua and Barbuda
- Czech Republic
- Gambia, The
- Hong Kong SAR, China
- Korea, Rep.
- New Zealand
- Puerto Rico
- Russian Federation
- Saudi Arabia
- Slovak Republic
- South Africa
- United Kingdom
- United States
- Adult Mortality
- Cancer Survival
- Cause Of Death
- Childhood Leukaemia
- Data Protection
- Effectiveness Evaluations
- Epidemiological Methods
- General Practice Data
- Global Health Initiatives
- Liver Cancer
- Longitudinal And Survival Data
- Low And Middle Income Countries
- Missing Data
- Multiple Imputation
- Population Health Science
- health systems and social inequalities
- mortality trends
40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study.
Quaresma, M.; Coleman, M.P.; Rachet, B.;
Lancet, 2015; 385(9974):1206-18
Funnel plots for population-based cancer survival: principles, methods and applications.
Quaresma, M.; Coleman, M.P.; Rachet, B.;
Stat Med, 2014; 33(6):1070-80
Cancer incidence, survival and mortality: Explaining the concepts.
Ellis, L.; Woods, L.M.; Estève, J.; Eloranta, S.; Coleman, M.P.; Rachet, B.;
Int J Cancer, 2014; 135(8):1774-82
Cancer survival: global surveillance will stimulate health policy and improve equity
Lancet, 2014; 383(9916):564-573
Breast cancer survival in the US and Europe: A CONCORD high-resolution study.
Allemani, C.; Sant, M.; Weir, H.K.; Richardson, L.C.; Baili, P.; Storm, H.; Siesling, S.; Torrella-Ramos, A.; Voogd, A.C.; Aareleid, T.; Ardanaz, E.; Berrino, F.; Bielska-Lasota, M.; Bolick, S.; Cirilli, C.; Colonna, M.; Contiero, P.; Cress, R.; Crocetti, E.; Fulton, J.P.; Grosclaude, P.; Hakulinen, T.; Izarzugaza, M.I.; Malmström, P.; Peignaux, K.; Primic-Žakelj, M.; Rachtan, J.; Safaei Diba, C.; Sánchez, M.J.; Schymura, M.J.; Shen, T.; Traina, A.; Tryggvadottir, L.; Tumino, R.; Velten, M.; Vercelli, M.; Wolf, H.J.; Woronoff, A.S.; Wu, X.; Coleman, M.P.;
Int J Cancer, 2013; 132(5):1170-81
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.
Coleman, M.P.; Forman, D.; Bryant, H.; Butler, J.; Rachet, B.; Maringe, C.; Nur, U.; Tracey, E.; Coory, M.; Hatcher, J.; McGahan, C.E.; Turner, D.; Marrett, L.; Gjerstorff, M.L.; Johannesen, T.B.; Adolfsson, J.; Lambe, M.; Lawrence, G.; Meechan, D.; Morris, E.J.; Middleton, R.; Steward, J.; Richards, M.A.; ICBP Module 1 Working Group (inc; Walters, S;)
Lancet, 2011; 377(9760):127-38
Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England.
Rachet, B.; Maringe, C.; Nur, U.; Quaresma, M.; Shah, A.; Woods, L.M.; Ellis, L.; Walters, S.; Forman, D.; Steward, J.; Coleman, M.P.;
Lancet Oncol, 2009; 10(4):351-69
What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable?
Abdel-Rahman, M.; Stockton, D.; Rachet, B.; Hakulinen, T.; Coleman, M.P.
British Journal of Cancer, 2009; 101:S115-S124
- → View all Professor Michel Coleman 's publications